A Case of Portal Hypertension after the Treatment of Oxaliplatin Based Adjuvant-Chemotherapy for Rectal Cancer.
10.4166/kjg.2011.57.4.253
- Author:
Jun HEO
1
;
Keun Young SHIN
;
Yong Hwan KWON
;
Soo Young PARK
;
Min Kyu JUNG
;
Chang Min CHO
;
Won Young TAK
;
Young Oh KWEON
Author Information
1. Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. yokweon@mail.knu.ac.kr
- Publication Type:Case Report ; English Abstract
- Keywords:
Portal hypertension;
Esophageal varix;
Splenomegaly;
Oxaliplatin
- MeSH:
Adult;
Antineoplastic Agents/*adverse effects/therapeutic use;
Chemotherapy, Adjuvant;
Esophageal and Gastric Varices/chemically induced;
Female;
Fibrosis;
Humans;
Hypertension, Portal/chemically induced/*diagnosis;
Liver/pathology;
Organoplatinum Compounds/*adverse effects/therapeutic use;
Positron-Emission Tomography;
Rectal Neoplasms/*drug therapy/surgery;
Splenomegaly/chemically induced;
Tomography, X-Ray Computed
- From:The Korean Journal of Gastroenterology
2011;57(4):253-257
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We report herein a case of 35-years-old woman in whom portal hypertension (esophageal varix and splenomegaly) developed after 12 cycles of oxaliplatin based adjuvant chemotherapy for rectal cancer. She was transferred for the evaluation of etiology of new-onset portal hypertension. The esophageal varix and splenomegaly were absent before the oxaliplatin based adjuvant chemotherapy. Thorough history taking and serological exam revealed no evidence of chronic liver disease. Liver biopsy was done and there was no cirrhotic nodule formation. Instead, perivenular fibrosis was noted. Considering new development of esophageal varices and splenomegaly after 12 cycles of oxaliplatin-based adjuvant chemotherapy, we could conclude that portal hypertension in this patient were due to sinusoidal injury by oxaliplatin. Finally, we recommend regular follow-up with endoscopy and radiologic examination for checking the development of varices and for screening of varices and splenomegaly in patients with colo-rectal cancer who receive oxaliplatin-based chemotherapy.
